Delphi Genetics
2001
FOUNDED
PRIVATE
STATUS
11-20
EMPLOYEES
Later Stage VC
LATEST DEAL TYPE
$1M
LATEST DEAL AMOUNT
4
INVESTORS
Description
Developer of molecular tools designed to offer deoxyribonucleic acid engineering services. The company's Staby, is very flexible and used for synthetic biology, allowing successful cloning of genes and expression of recombinant proteins at a higher yield, enabling researchers to reach their goal faster and more efficiently.
Website
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Primary Office
- Rue A. de Saint-Exupéry, 5
- Gosselies
- 6041 Charleroi
- Belgium
+32 071 00 00 00
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore Delphi Genetics’s full profile, request a free trial.
Delphi Genetics Valuation and Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 1. Later Stage VC | 10-Mar-2015 | $1M | 000 | Completed | Startup |
Delphi Genetics Investors (4)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Board Seat |
Contact Info |
|---|---|---|---|---|---|---|
| Invest4 DelphiG2 | Other | Minority | 000 0000 | 000000 0 | ||
| Michel Milinkovitch | Angel (individual) | Minority | 000 0000 | 000000 0 | ||
| SAMBRINVEST | Venture Capital | Minority | 000 0000 | 000000 0 | ||
| Université Libre de Bruxelles | Other | Minority | 000 0000 | 000000 0 |